Jed G. Nuchtern, MD
Department or Service
- Texas Medical Center
Chief of Pediatric Surgery
Texas Children's Hospital
William J. Pokorny Endowed Chair in Pediatric Surgery, Baylor College of Medicine
Professor of Surgery and Pediatrics, Baylor College of Medicine
|Baylor College of Medicine||residency||Pediatric Surgery||1995|
|University of Washington||residency||General Surgery||1992|
|University of Washington||residency||General Surgery||1988|
|University of Washington||internship||General Surgery||1986|
|Harvard Medical School||medical school||Doctor of Medicine||1985|
Dr. Nuchtern is a pediatric surgeon specializing in pediatric surgical oncology. In addition to performing general neonatal and pediatric surgery, he is a member of the Surgical Oncology Team at Texas Children's Hospital and is actively involved with taking care of patients with neuroblastoma, liver cancer, renal tumors and sarcomas. In his general surgery practice, Dr. Nuchtern also has specialized expertise in pectus excavatum and carinatum repair.
Dr. Nuchtern is certified by the American Board of Surgery in General Surgery, Pediatric Surgery and Surgical Critical Care.
|American Academy of Pediatrics (AAP), Surgical Section||Fellow|
|American College of Surgeons (ACS)||Fellow; Member, Commission on Cancer|
|American Pediatric Surgical Association||Member|
|Association for Academic Surgery||Member|
|Commission on Cancer, American College of Surgeons||Member|
|International Society for Pediatric Surgical Oncology||Member|
|Pediatric Oncology Group/Children's Oncology Group (COG)||Member|
|Society of Critical Care Medicine||Member|
|Society of University Surgeons||Member|
|Southwestern Surgical Congress||Member|
Dr. Nuchtern's research program includes translational and clinical research on developing new treatments for pediatric solid tumors, particularly neuroblastoma. The primary focus in the laboratory is identifying new targets for neuroblastoma therapy; current research is directed toward identifying the pathways through which these molecules affect tumor progression. In addition to these translational studies, Dr. Nuchtern is involved in clinical research on neuroblastoma in infants. Through the Children's Oncology Group, he designed and implemented a prospective international study investigating the safety and efficacy of expectant observation as the primary treatment modality for infants with low risk adrenal tumors. He is a member of the Carl C. Anderson, Sr. and Marie Jo Anderson Charitable Foundation Laboratory for Neuroblastoma Research as well as the Texas Children's Liver Tumor Center.
Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, shi Y, Patel R, Vasudevan SA, Zage PE, Zhang H, Nuchtern JG, Kim ES, Fu S, Yang J. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis 2015 Jan;20(1):50-62. PMID:25425103.